



Prof F E Smit
Department of Cardiothoracic Surgery
Faculty of Health Sciences
University of the Free State
April 2010



CARDIOTHORACIC SURGERY – COMPLEX SIMPLICITY OR SIMPLE COMPLEXITY?



Complexity Theory

- A set of concepts that attempts to explain complex phenomena not explainable by traditional (mechanistic) theories
- Integrates ideas from chaos theory, cognitive psychology, computer science, evolutionary biology, general systems theory, fuzzy logic, information theory and related fields
- Deals with natural and artificial systems as they are and not by simplifying them (constituent parts)
- Recognises that complex behaviour emerges from simple rules
- All complex systems are networks of many interdependent parts interacting according to these rules


Rheumatic Heart Disease in Children

- Table 2: Estimated number of cases in 5 to 14-yr olds, reported 2003 WHO, The Atlas of Heart Disease and stroke

Sub-Saharan Africa 1 008 207	China 176 576	South-Central Asia 734 786
Asia (other) 101 822	Latin America 136 971	Eastern Mediterranean & North Africa 153 679
Eastern Europe 40 366	Pacific 7 744	Industrialised Countries 33 330


WHO PROJECTIONS

LEADING CAUSE OF DEATH - DEVELOPING WORLD



Number of Open Hearts

- Figure 1: Number of open-heart operations per million in selected regions (Pezzella, 2002)





Cardiac Surgery in SA in 2003

- **Sustainability**

Inefficiency

Lack of alternatives, strategic planning, leadership

- **Academic Excellence:**

Training and standards

Surgical exposure

Leadership?




Service delivery


Adult Cardiac Surgery



Pediatric Cardiac Surgery



Thoracic Surgery







***You've got to be very careful if you don't know where you're going
because you might get there...***

-- Yogi Berra


Research Domains




The ATLAS model – Linegar PhD



Step 1. The Situational Analysis




Step 2. Operational planning cycle




Step 3. Implement solution


Step 4. Regional Hosp actions




Step 5. Referral chain actions




Step 6. Actions UH Resource Elements




Step 6.1 UH OPD actions



Step 6.2 UH Theatre actions




Step 7. Actions UH Functional Elements



Step 8. Database



Step 9. Performance Measures



Sustainability and Risk Management

National Adult Cardiac Database

UNIVERSITEIT VAN DIE VRYSTAAT
UNIVERSITY OF THE FREE STATE
YUNIVESITHI YA FREISTATA

Direkteur: Fakulteitsadministrasie / Director: Faculty Administration
Fakulteit Gesondheidswetenskappe / Faculty of Health Sciences

Research Division
Internal Post Box 040
(051) 4052812
Fax nr (051) 4444355

E-mail address: gndkhs.md@mail.uovs.ac.za

Ms H Strauss 2008-03-14


PROF FE SMIT
DEPT OF CARDIOTHORACIC SURGERY
FACULTY OF HEALTH SCIENCES
UFS

Dear Prof Smit

ETOVS NR 46/08 DEPT OF CARDIOTHORACIC SURGERY
PROF FE SMIT
PROJECT TITLE: THE SOUTH AFRICAN HEART ASSOCIATION DATABASE.
(CARDIAC SURGERY NATIONAL DATABASE AND CATHLAB REGISTRY).

- You are hereby informed that The Ethics Committee approved the above-mentioned at the meeting on 11 March 2008.
- Committee guidance documents: Declaration of Helsinki, ICH, GCP and MRC Guidelines on Bio Medical Research, Clinical Trial Guidelines 2000 Department of Health RSA; Ethics in Health Research: Principles Structure and Processes Department of Health RSA 2004; the Constitution of the Ethics Committee of the Faculty of Health Sciences and the Guidelines of the SA Medicines Control Council as well as Laws and Regulations with regard to the Control of Medicines.
- Any amendment, extension or other modifications to the protocol must be submitted to the Ethics Committee for approval.
- The Committee must be informed of any serious adverse event and/or termination of the study.
- A progress report should be submitted within one year of approval of long term studies and a final report at completion of both short term and long term studies.
- Kindly refer to the ETOVS reference number in correspondence to the Ethics Committee secretariat.

Yours faithfully

for 
PROF BB HOEK
CHAIR: ETHICS COMMITTEE

339, Bloemfontein 9300, RSA (051) 405 2812 gndkhs.md@ufs.ac.za
Republiek van Suid-Afrika / Republic of South Africa

Add event

Please select or add a patient to begin...

Patient	History	Risk	Investigation	EuroScore	Operative	Valves	Aorta	Myocardial	Post-operative
Patient Factors Age: 48 years Sex: <input type="checkbox"/> Chronic pulmonary disease: <input type="checkbox"/> Extracardiac ateriopathy: <input type="checkbox"/> Neurological dysfunction: <input type="checkbox"/> Previous cardiac surgery: <input type="checkbox"/> Serum creatinine > 200 µmol/L: <input type="checkbox"/> Active endocarditis: <input checked="" type="checkbox"/> Critical preoperative state: <input checked="" type="checkbox"/>									
Cardiac Factors Unstable angina: <input type="checkbox"/> LV dysfunction moderate or LVEF 30-50%: <input checked="" type="checkbox"/> LV dysfunction poor or LVEF <30%: <input type="checkbox"/> Recent myocardial infarct: <input type="checkbox"/> Pulmonary hypertension: <input checked="" type="checkbox"/>									
Operation Factors Emergency: <input checked="" type="checkbox"/> Other than isolated CABG: <input checked="" type="checkbox"/> Surgery on thoracic aorta: <input type="checkbox"/> Postinfarct septal rupture: <input type="checkbox"/>									
Logistic EuroScore (mortality %) = 43.19%									

? Help X Close ✓ Save





Pulmonary Hypertension

- Late presentation of congenital cardiac disease is endemic in the developing world
- In our patient population (UFS) of VSD and AVSD, pulmonary hypertension is present in 43,4% (Woods Units > 3.5)
- 16,2% has severe pulmonary hypertension (Woods Units > 6) at presentation
- Predicting reversibility of advanced PHT is a challenge


Stages/grades in Pulmonary hypertension:

FIGURE 1. Pathophysiology of Pulmonary Hypertension







Coronary Artery Disease

- Acute Coronary Syndrome
 - On-pump versus off- pump Surgery
 - Longitudinal observational analytical cohort study
- 


Procedural Risk



Risk factor analysis in predicting surgical outcomes in acute coronary syndromes: A proposal for an integrative risk model

Micro-circulation – Cellular

Evaluating the relationship of lactate and glucose levels and operative SIRS in CABG patients



SIRS in CABG patients - Inflammatory Markers

The Median (Inter-quartile) changes


	Pre-operative Baseline		Post-operative 24 hours		Post-operative 48 hours		Post-operative 72 hours		Post-operative 96 hours		Post-operative 120 hours	
	On-pump CPB	OPCAB	On-pump CPB	OPCAB	On-pump CPB	OPCAB	On-pump CPB	OPCAB	On-pump CPB	OPCAB	On-pump CPB	OPCAB
Total = n	30	30	30	30	30	30	30	30	27	26	14	16
CRP (mg/l) Median	15.5	13.9	103.3 5	101.85	117	111.65	69.8	83.45	47.9	70.8 *	46.4	57.10 *
25th & 75th Percentile	6.3 - 35.7	2.9 - 39.0	85.0 - 116.3	66.4 - 137.7	89.0 - 150.4	79.7 - 130.3	45.5 - 127.9	49.3 - 106.7	33.9 - 74.4	44.2 - 90.6	29.4 - 79.7	39.5 - 95.4
PCT (µg/l) Median	0.07	0.08	1.82 ***	0.47	1.23 ***	0.41	0.79 ***	0.24	0.49 *	0.35	0.27	0.18
25th & 75th Percentile	0.06 - 0.11	0.05 - 0.10	1.10 - 4.75	0.19 - 2.21	0.69 - 3.11	0.16 - 1.48	0.44 - 1.76	0.14 - 0.83	0.31 - 1.01	0.14 - 0.85	0.19 - 0.87	0.10 - 0.45
IL-6 (ng/l) Median	0	0	76.29	96.18 *	38.66	70.92 **	12.08	32.7 **	6.4	37.9 ***	11.37	31.31 *
25th & 75th Percentile	0.0 - 5.3	0.0 - 33.4	39.9 - 128.8	42.5 - 135.6	14.8 - 86.3	36.3 - 128.0	0.9 - 48.0	17.0 - 50.9	0.0 - 34.9	12.9 - 69.9	0.0 - 47.8	15.2 - 76.8
TNF α (ng/l) Median	7.62	13.00 *	6.03	9.07	10.27	12.78	11.72	13.15	12.46	14.91	13.7	13.4
25th & 75th Percentile	6.5 - 12.5	7.8 - 16.7	4.6 - 15.4	6.1 - 14.5	6.7 - 15.1	9.0 - 15.8	7.4 - 22.5	10.8 - 21.1	7.3 - 22.3	9.8 - 20.7	10.8 - 21.9	9.9 - 18.8
WCC (10 ⁹ /l) Median	8.9	9.05	19.20 **	15.67	19.44 ***	13.92	15.30 ***	11.37	11.95	11.03	11.74	9.88
25th & 75th Percentile	7.8 - 10.8	7.0 - 10.6	15.5 - 25.6	12.4 - 16.2	15.0 - 24.1	11.9 - 16.8	12.8 - 19.4	8.7 - 13.0	10.8 - 13.8	9.5 - 12.7	9.9 - 13.0	9.2 - 13.0
Neutrophils (10 ⁹ /l) Median	5.22	5.1	15.35 *	11.39	14.57 **	10.96	10.57 ***	7.54	8.53	7.12	7.92 *	6.43
25th & 75th Percentile	4.1 - 6.9	4.1 - 6.4	10.9 - 19.7	9.7 - 13.7	11.8 - 19.3	9.0 - 13.7	9.6 - 14.6	5.8 - 9.7	7.0 - 10.1	5.7 - 8.2	6.2 - 9.1	5.6 - 7.8
Lymphocytes (10 ⁹ /l) Median	2.76 *	2.36	1.30 **	0.96	1.91	1.58	2.28	1.97	2.44 **	2.26	2.3	2.02
25th & 75th Percentile	2.22 - 3.08	1.86 - 3.15	1.07 - 1.87	0.75 - 1.54	1.37 - 2.58	1.17 - 2.22	1.75 - 2.88	1.47 - 2.35	2.00 - 3.19	1.64 - 2.82	1.73 - 3.64	1.71 - 2.96
Lymphocytes (10 ⁹ /l) Median	0.64	0.54	1.47 *	0.98	0.98	0.97	0.89	0.77	0.76	0.74	0.89	0.91
25th & 75th Percentile	0.57 - 0.91	0.46 - 0.86	0.81 - 2.06	0.79 - 1.35	0.68 - 1.27	0.82 - 1.20	0.69 - 1.29	0.70 - 1.12	0.63 - 0.97	0.65 - 0.95	0.71 - 1.13	0.75 - 1.18
Neutrophil/Lymphocyte ratio (10 ⁹ /l) Median	2.05	1.9	10.87	10.09	7.6	6.68	5.19 **	3.93	3.27	3.61	2.83	3.27

*p<0.1; **p<0.05; ***p<0.01; and ****p<0.001

Inflammatory Marker Comparison Between Patients with Acute Coronary Syndrome undergoing On-Pump versus Off-Pump Coronary Artery Bypass Graft Surgery


END STAGE HEART DISEASE

Posterior LV Infarction- tethering of leaflets





Functional MR Pathophysiology

- ⊙ Normal MV function requires coordinated dynamics of all components
- ⊙ LA
- ⊙ Annulus
- ⊙ Leaflets
- ⊙ Chordae
- ⊙ Papillary muscle
- ⊙ Ventricle



A Finite Element Study (Bolling 2007)



White, HD Circulation 1987




Figure 2: A. Relationship between LV end-systolic volume and mortality. Note (1) that volume is in milliliters, not milliliters per square meter, so that the LV end-systolic volume index would be twice this number if patient size were 2 m² and (2) that volume increase is a surrogate for increased mortality. B. Comparison of prognosis in survivors and non-survivors in relationship to ejection fraction (solid line is at 35%) and LV end-systolic volume in milliliters. Note that lower LV end systolic volume at 35% ejection fraction is associated with reduced mortality in survivors compared with increased mortality in non-survivors when LV end-systolic volume is higher at 35% ejection fraction. MI, Myocardial infarction; LVESV, left ventricular end-systolic volume.

Ventricular Restoration

Rebuild ellipse




Figure 4: Changes in LV size and shape after SVR. The elliptical normal form (A) becomes spherical after anterior septal infarction (B). Size and shape are returned toward a more normal elliptical configuration by placing a patch to exclude the scar and returning nonscarred remote muscle back to its conical form (C). Adapted from: Buckberg G. Ventricular Structure and surgical history. Adapted from: Heart Failure Rev. 2005; 9: 255-68.



The Heart Valve Dilemma

- The ideal prostheses does not exist yet
- Research and development aimed at first world countries with aging populations and sophisticated follow-up
- Complicated and extremely expensive developing and licensing process
- Lack of new concepts (mechanical valves -1977)
- Exciting (but slow progress) with tissue engineering
- Majority of potential valve recipients live in the developing world
- They are young
- **Their countries are developing and becoming more affluent**

Prosthetic heart valves: Catering for the few




Fig. 1. Typical age-distribution of patients undergoing heart valve replacement in the First World and in a Developing Country. While prosthetic valve recipients in a First World population are predominantly in the age group of 60–69 years (red line) they are broadly disseminated over an age spectrum from 20 to 70 years in a Developing Country such as South Africa (blue line). As the age distribution of 2000 consecutive heart valve recipients at the Groote Schuur Hospital (University of Cape Town) shows, a significant proportion of patients is even younger than 20 years.

When Reconstruction Fails or is Not Feasible: Valve Replacement Options in the Pediatric Population




Figure 7 Freedom from reoperation after initial AVR stratified by prosthetic type. A multivariable equation was constructed for remaining alive after initial AVR without subsequent valve replacement according to the original competing risk model and forcing all valve types into the equation. The resulting model was then solved for a hypothetical 10-year-old patient of 40 kg undergoing operation in 1990. The autograft has superior longevity, whereas the tissue valves and the allografts have considerably worse durability. The numbers in parentheses represent the total number of AVR episodes for each prosthesis type.




Harvested Homografts



Role of Homograft Bank

■ Aortic ■ Pulmonary



Durban	JHB General	JHB Private	PTA General	PTA Private	CT Academic	CT Private	Universitas	Medi-Clinic	Germany	PE
64	100	64	46	98	102	81	497	38	55	21


Current Research



1. Sheep Model





2. Homograft




3. Implantation




4. Post-operative Care




SEM



Tensile Strength




DSC




H & E


Degree of calcification (von Kossa)




Glutaraldehyde



Aluminium




Glycosaminoglycans



Glycar

Superficial binding of GAGs to the outer surface of pericardium



Prosthetic heart valves: Catering for the few



Fig. 8. Polymeric heart valves: (a) a frame machined from polyetheretherketone (PEEK) and coated with a thin layer of leaflet polyurethane. Leaflets of a commercially available polyetherurethane suitable for animal implantation (Estane 58315, BF Goodrich, Westerlo-Oevel, Belgium) were dip-coated onto the frame. This valve design has achieved durabilities in excess of 400 million cycles (10.5 years) during in vitro fatigue testing [162]; (b) and (c): polycarbonate urethane (PCU) tri-leaflet and bi-leaflet valves intended for the aortic and mitral positions. These particular designs achieved in vitro durabilities of up to 600 million (15.8 years) and 1 billion (26 years) cycles, respectively.

Polyurethane: material for the next generation of heart valve prostheses?




Fig. 2. Porcine valve viewed in situ immediately prior to explant. (a) Inflow surface; (b) outflow surface; (c) radiograph of explant porcine valve.

Fig. 2. Porcine valve viewed in situ immediately prior to explant. (a) Inflow surface; (b) outflow surface; (c) radiograph of explant porcine valve.

Polyurethane: material for the next generation of heart valve prostheses?




Fig. 3. Explant polyurethane valve viewed in situ immediately prior to explant. (a) Inflow surface; (b) outflow surface; (c) radiograph of explant polyurethane valve.

Fig. 3. Explant polyurethane valve viewed in situ immediately prior to explant. (a) Inflow surface; (b) outflow surface; (c) radiograph of explant polyurethane valve.

Impact of Design Parameters on Bileaflet Mechanical Heart Valve Flow Dynamics




Figure 7: Plots of vorticity contours (left column), shear stress (center column) and the platelet activation parameter (right column) of (a) Valve 1 and (b) Valve 2 at 12 ms after the instant of valve closure. In the activation parameter plots, the bright red regions indicate a higher potential for platelets to be activated, while dark blue regions represent the minimal potential for the same. Larger regions of bright red for Valve 2 indicate a higher potential for platelet activation compared to Valve 1 during the initial impact and rebound phases of valve closure.






Figure 8: Plots of vorticity contours (left column), shear stress (center column) and the platelet activation parameter (right column) of (a) Valve 1 and (b) Valve 2 at 18 ms after the instant of valve closure. In the activation parameter plots, the bright red regions indicate a higher potential for platelets to be activated, while dark blue regions represent the minimal potential for the same. Larger regions of bright red for Valve 2 indicate a higher potential for platelet activation compared to Valve 1 during the initial impact and rebound phases of valve closure.

Flow dynamic modulation models



“The African Valve”

Fig. 12. Image of the “ValveXchange” transapically exchangeable bioprosthetic heart valve. Rather than being a permanent valve, the exchangeable valve is a two-piece device with leaflets that can be replaced after having worn out. In the main image, the exchange process is shown through the apex of the heart. A special trocar locks onto the “docking station” (the sewing cuff and valve stent) to stabilize the heart and valve, and a valve removal tool is inserted. The stent posts are grasped, the valve lifted from the docking station, collapsed and pulled out through the trocar. A new valve is immediately inserted and the procedure is done completely off-pump. The inset image shows a retrograde approach, in which a similar valve holder is passed from the outflow aspect to lock on to the docking station. In this approach, the valve is passed over the shaft of the valve holder during the exchange ([212], with permission





Sustainability

- Education


 - Resource Allocation and the relationship between Medicine and Society
- 



The African Surgeon

- Maximum impact at lowest cost
- Expand role
- Be a physician

Diagnostics in Africa:

- 
- ECG/ CXR/FBC/MC&S/biochemistry
 - Echo- Cardiography
 - CT Scanning
 - Absence of Cathlabs



African Curriculum

- General Thoracic Surgery
- Palliative paediatric cardiac surgery – Pulmonary artery banding/shunts
- Off pump paediatric surgery – PDA, Coarctation
- Closed mitral valvotomy
- Off pump coronary artery surgery
- ? Trans apical off pump valve replacements with new technology



African School

- Hannes Meyer Registrar Conference
- UFS, SCTSSA 2004 -2008
- EACTS – 2010
- CTSnet
- Active Intake requested by Ghana



Curriculum:


- Cardiac and Thoracic Surgery
- Intensive Care
- Diagnostic Procedures and Imaging
- Management



Complexity of Academic Medicine

- National Healthcare Policy
- Service Delivery – National Health
- Training – National Education
- Research – National Education
- Sustainability- National Treasury
- Provincial Authorities and Health Acts
- Local Government level

OVERALL MORTALITY PROFILE SA



Stats SA., 2005

LOCAL DEMOGRAPHICS



Sub-Saharan Africa

- 750 + million

Year	Male population	Female population	Total population
2010	13,200,000	13,200,000	26,400,000
2011	13,300,000	13,300,000	26,600,000
2012	13,400,000	13,400,000	26,800,000
2013	13,500,000	13,500,000	27,000,000
2014	13,600,000	13,600,000	27,200,000
2015	13,700,000	13,700,000	27,400,000
2016	13,800,000	13,800,000	27,600,000
2017	13,900,000	13,900,000	27,800,000
2018	14,000,000	14,000,000	28,000,000
2019	14,100,000	14,100,000	28,200,000
2020	14,200,000	14,200,000	28,400,000

South Africa (Stats SA)

- 47 + million



Central SA

- 4.2 million
- 5.9 million incl. Lesotho

Year	Male population	Female population	Total population
2010	1,400,000	1,400,000	2,800,000
2011	1,400,000	1,400,000	2,800,000
2012	1,400,000	1,400,000	2,800,000
2013	1,400,000	1,400,000	2,800,000
2014	1,400,000	1,400,000	2,800,000
2015	1,400,000	1,400,000	2,800,000
2016	1,400,000	1,400,000	2,800,000
2017	1,400,000	1,400,000	2,800,000
2018	1,400,000	1,400,000	2,800,000
2019	1,400,000	1,400,000	2,800,000
2020	1,400,000	1,400,000	2,800,000


Free State

- 2.9 million

Age	Male population	Female population	Total population
0 - 4 Years	150,100	148,500	298,600
5 - 9 Years	151,400	149,700	301,100
10 - 14 Years	153,000	151,200	304,200
15 - 19 Years	156,700	153,500	310,200
20 - 24 Years	146,700	144,200	290,900
25 - 29 Years	129,800	129,600	259,400
30 - 34 Years	115,300	119,400	234,700
35 - 39 Years	90,600	96,200	186,800
40 - 44 Years	78,000	84,100	162,100
45 - 49 Years	72,100	76,000	148,100
50 - 54 Years	60,300	65,400	125,700
55 - 59 Years	46,400	53,000	99,400
60 - 64 Years	40,800	45,600	86,400
65 - 69 Years	28,200	33,000	61,200
70 - 74 Years	19,800	25,700	45,500
75 - 79 Years	10,300	13,500	23,800
80+ Years	7,600	13,100	20,700
Total	1,457,100	1,501,700	2,958,800

Mid-year population estimates - breakdown for the Free State Province, 2006

What are the causes of ill-health in South Africa? SA NBD study 2000



Source: Revised South African National Burden of Disease Estimates for 2000
Norman et al. 2006

Key messages from *The Lancet South Africa Series*


1. Problem of colliding epidemics: 15 years after its first democratic election and liberation from apartheid, South Africa faces colliding epidemics – explosive HIV and TB epidemics, a high burden of chronic illness, mental health disorders, injury and violence-related deaths as well as a silent epidemic of maternal, neonatal, and child mortality. South Africa's per capita health burden is the highest of any middle-income country in the world. The brunt of all these disease burdens is still carried by the poorest families.
2. Paradox of supportive policies with moderate spending on health, yet worsening health outcomes. The extra health burden means more investment in health systems, at least in the medium term, and more effective implementation and effective management at all levels is needed.
3. Pressure on the health system, especially at district level to cope with the heavy burden of disease. There is also a disconnect between the public and private sectors. The priorities are:
 - prevention - whether for infections (notably HIV and TB), non-communicable diseases, injury, or for maternal, neonatal and child health (especially prevention of mother-to-child HIV transmission [PMTCT] and improved newborn health).
 - primary health care that is integrated and effective with strong management and capable use of data.
 - practising widespread scale up of successful innovations and relevant and rigorous clinical research.
4. Potential for change: South Africa could be on track for the Millennium Development Goals (MDGs) and reduce other epidemics with strategic investment, implementation, leadership and accountability for public and private sectors. Civil society has been key in promoting action for HIV/AIDS and could play a more powerful role for the wider health agenda in South Africa.



A Point of Departure

What does the Constitution say?

- Free Access
 - Services limited by available resources

 - What does that mean and how does it translate to service, training and research institutions?
- 

Reality

What is Government doing?

- Maternal Mortality, Pediatric Mortality figures
- Life expectancy

Collapse of Systems

- TB/HIV/Primary Health Care
- Hospital services
- Training platforms
- Research
- Human Resources – present and future

Problem Statement:

Current model:

Based on **SUPPLY**:


- Levels of care
based on
- Available services
based on
- Clinical expertise
determines
- Capacity
trusts
- Acuity

Self justifying
(supply side capacity is validated by
supply side capacity)

Alternative Model:

Based on **DEMAND**

- Burden of disease
leads to
- Case Mix
assessed by
- Severity and Volume
determines
- Expertise & Staff
Ratio
enables
- Monitoring &
resource planning



Case Mix
(determines structure)

The R 1440 and R9000 annual per capita spending and the unequal service dilemma (2006)

- $47\,000\,000 * R\,9000(2006) = R423$ billion
- $47\,000\,000 * R1440$ (FS 2006) = R 67 .8 billion
- Unequal services
- NHI - Universal and equal care (?R 290 billion)


Population distribution (Public vs Private)

Population distributions: Male



— Medscheme — FS population

Population distributions: Female




— Medscheme — FS population


Ideal Admission rate (Non - communicable Disease)

Admissions per 1000 population superimposed on the FS population

Medscheme admissions



Expected hospital admissions for the FS





Utilisation- Hospitalisation

- Utilisation = 221/1000 in Medscheme
- Average cost of R 15100.34 per event
- FSHS = 173/1000 planned hospitalisation (76% of above)
- Actual Hospitalisation = 93/1000
- 15/1000 are deemed tertiary

Category	Cost/ admit		Cost/ admit		Cost/ admit		Cost/ admit
Pneumonia	10,000						
		Co-morbidity					
Pneumonia		none	9,000				
Pneumonia		with	10,500				
Pneumonia		Major	13,000				
				Medstat			
				Disease			
				Stage			
Pneumonia		none		1	8,000		
Pneumonia		none		2&3	11,000		
Pneumonia		with		1	10,000		
Pneumonia		with		2&3	12,000		
Pneumonia		Major		1	12,500		
Pneumonia		Major		2&3	15,000		
						Age Band	
Pneumonia		none		1		<20	8,500
Pneumonia		none		1		20 - 60	7,000
Pneumonia		none		1		>60	9,000
Pneumonia		none		2&3		<20	11,500
Pneumonia		none		2&3		20 - 60	10,000
Pneumonia		none		2&3		>60	12,500
Pneumonia		with		1		<20	10,500
Pneumonia		with		1		20 - 60	9,000
Pneumonia		with		1		>60	11,500
Pneumonia		with		2&3		<20	12,500
Pneumonia		with		2&3		20 - 60	11,000
Pneumonia		with		2&3		>60	15,000
Pneumonia		Major		1		<20	13,000
Pneumonia		Major		1		20 - 60	11,500
Pneumonia		Major		1		>60	14,000
Pneumonia		Major		2&3		<20	15,500
Pneumonia		Major		2&3		20 - 60	13,500
Pneumonia		Major		2&3		>60	17,000

Risk adjustment / Predictive Modeling

Case mix analysis as a necessary tool for specialist training
 Dr Brian Ruff, General Manager Clinical Risk Management,
 Discovery Health




Service package

- Quadruple Burden of Disease
- Clear objectives and strategies per quadrant
- Recognize the effect of socio-economic status, responsible social behaviour and effective government agencies
- Ring fence budgets per quadrant
- Outsource actuarial services
- Address Universal vs Two Tier system
- Universal Tax = VAT



Rights of the Health Care Worker

- Respect role in determining Quality and Quantity of Service delivery
 - Medical legal position of personnel
 - Rationing of services
 - Working conditions (e.g. HIV, Safety)
 - Remuneration packages
- 




The Right to Quality Training

- Training accreditation- HPCSA, SAQA, Higher Education Commission
 - Training Institutions – CMSA, UFS, Deans Committee
 - Professional Societies – SAMA and Affiliates (e.g. CTSSA)
- 



What are the rights of Patients?

- Human Rights Commission
 - Ethical Committee of HPCSA
 - Ethics SA and other Institutions
 - Ombudsman
- 



The truth is rarely pure, and never
simple

Oscar Wilde



Simplicity

- Thoracic surgery
- Rheumatic fever prevention
- Detection and treatment of congenital heart disease
- New Heart Valve technology
- Coronary artery disease prevention
- Thrombolysis and Revascularisation programs
- End stage heart Programs
- African program



Complexity – Who is responsible?





Simplicity

Establish a Legal Framework for Health Care Delivery
In SA

- Negotiated settlements
- Case Law
- Class Action

Establish Policy and Outsource Health Care

- Service package design, actuarial analyses
- Strategic Planning
- Management of all aspects of healthcare by professionals



Honesty, Integrity, Ability and Transparency

- Legal and Statutory Framework
- Risk Management Models for the Population
- Priorities and Rationing Principles
- Service Delivery related to Burden of Disease
- Appropriate Training
- Suitable Training Platforms
- Translational Research
- Appropriate Resource/Budget Allocations
- Outcomes Measurement
- Operational Efficiency and Management
- **Simple Rules for A Complex System**



Complexity – Deterrence and chaos

- $d_{yt+1} = (w_x)(c_{xt})(1-c_{xt}) - d_{xt}$

and

- $d_{xt+1} = (w_y)(c_{yt})(1-c_{yt}) - d_{yt}$

- The control parameter is w , the perceived will of the deterring country and of its potential adversaries

SA Health Reform



“Learn to do good; seek justice, correct oppression;
bring justice to the fatherless,
plead the widow’s cause”

- Isaiah 1: 17

“Blessed are the merciful, for they shall obtain
mercy”

-Matthews 5 :7

‘Those who spend their wealth by night or day, in
secret or in public, they shall have their reward with
their Lord. On them shall be no fear nor shall they
grieve.’

-Al Qur’an (2:274)

“We are all in the gutter, but some of us are looking
at the stars”

- Oscar Wilde

Lord Darlington, Act III

Lady Windermere's Fan (1892)



Thanks

Mentors

- Hannes Meyer, Japie Hough, Marc De Leval, Jarda Stark, Donald Ross, Rob Kinsley, David Wheatley, Bob Frater, Sir Bruce Keogh, Marko Turina
- Colleagues
- Family and Friends
- Sponsors